This study aims to evaluate the efficacy and safety of venetoclax combined with azacitidine and mitoxantrone hydrochloride liposome (MVA) versus idarubicin combined with cytarabine (IA) in the treatment of newly diagnosed AML.
1. The patient fully understands the study, voluntarily participates, and has signed the informed consent form (ICF).
Acute promyelocytic leukemia (APL);
Central nervous system leukemia (CNSL);
AML secondary to chemotherapy/radiotherapy for other malignancies or antecedent hematological disorders (e.g., MDS, MPN, CML);
Prior treatment with hypomethylating agents (HMA) or venetoclax;
The First Affiliated Hospital of Soochow University
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Collaborator